

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: TOHYAMA *et al.*

APPLICATION NO.: NOT YET ASSIGNED

INTL. FILING DATE: 26 MARCH 2004

EARLIEST PRIORITY DATE: 28 MARCH 2003

FOR: COMPOSITION AND METHOD FOR NERVE REGENERATION

EXAMINER: NOT YET ASSIGNED

ART UNIT: NOT YET ASSIGNED

CONF. NO.: NOT YET ASSIGNED

**Information Disclosure Statement Within Three Months of
Application Filing or Before First Action – 37 CFR 1.97(b)**

Mail Stop PCT
 Attn: DO/EO/US
 Commissioner for Patents
 P. O. Box 1450
 Alexandria, VA 22313-1450

Sir:

1. Timing of Submission

This information disclosure is being filed within three months of the filing date of this application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever occurs last [37 CFR 1.97(b)]. The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information

- ☒ Copies of the following references are enclosed:
- ☒ All cited references except U.S. patents and/or published applications
 - ☐ References marked by asterisks
 - ☐ The following:
- ☐ Copies of the following references can be found in parent Application No. :
- ☐ All cited references
 - ☐ References marked by asterisks
 - ☐ The following:
- ☐ The following references are not in English. For each such reference, the undersigned has enclosed (i) a translation of the reference; (ii) a copy of a communication from a foreign patent office or International Searching Authority citing the reference, (iii) a copy of a reference which appears to be an

English-language counterpart, or (iv) an English-language abstract for the reference prepared by a third party. Applicant has not verified that the translation, English-language counterpart or third-party abstract is an accurate representation of the teachings of the non-English reference, though, and reserves the right to demonstrate otherwise.

- ☐ All cited references
- ☐ References marked by an asterisk
- ☐ The following:

3. Effect of Information Disclosure Statement (37 CFR 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.


4. Fee Payment

No fees are believed due. However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2207.

5. Patent Term Adjustment (37 CFR 1.704(d))

- ☐ The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).

Respectfully submitted,



Jacqueline F. Mahoney
Registration No. 48,390

Date: Sept. 28, 2005

Correspondence Address:
Customer No. 22918
Phone: 650 838-4300

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)	COMPLETE IF KNOWN		
	Application Number	not yet assigned 59150-8036	
	Title:	Composition and Method for Nerve Regeneration	
	Filed	September 28, 2005	
	First Named Inventor	TOHYAMA	
	Group Art Unit	not yet assigned	
	Examiner Name	not yet assigned	
	Atty Dkt No.	59150-8036	
Sheet 1 of 1		Confirmation No.	not yet assigned

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear
		NUMBER	Kind Code (if known)			
		6,242,416	B1	Gilchrest <i>et al.</i>	06/05/01	

FOREIGN PATENT DOCUMENTS								
Examiner Initial	Cite No.	Foreign Patent or Application			Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear	T
		Office	NUMBER	Kind Code (if known)				
		WO	01/19393	A	Collmer <i>et al.</i>	03/22/01		
		WO	95/11253	A	Barrett	04/27/95		

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
		YAMASHITA, T. <i>et al.</i> , "The p75 receptor acts as a displacement factor that releases Rho from Rho-GDI", <i>Nature Neuroscience</i> 6(5):461-467, 2003.	
		ILAG, L. L. <i>et al.</i> , "Selection of a peptide ligand to the p75 neurotrophin receptor death domain and determination of its binding sites by NMR", <i>Biochemical and Biophysical Research Communications</i> 255(1):104-109, 1999.	
		ILAG, L. L. <i>et al.</i> , "Biochemical and biophysical aspects of molecular recognition and signaling by neurotrophins", retrieved from the internet: URL: http://diss.kib.ki.se/1997/19971107ilag/ , 1997.	
		WONG, S. T. <i>et al.</i> , "A p75(NTR) and Nogo receptor complex mediates repulsive signaling by myelin-associated glycoprotein", <i>Nature Neuroscience</i> 5(12):1302-1308, 2002.	
		WOOLF, C.J. <i>et al.</i> , "It takes more than two to Nogo", <i>Science, U.S.</i> , 297:1132-1134, 2002.	
		YAMASHITA, T. <i>et al.</i> , "The p75 receptor transduces the signal from myelin-associated glycoprotein to Rho", <i>The Journal of Cell Biology</i> 157(4):565-570, 2002.	
		WANG, K. <i>et al.</i> , "P75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp", <i>Nature</i> 420(6911):74-78, 2002.	
		BOTCHKAREV, V. <i>et al.</i> , "A new role for p75 neurotrophin receptor in hair follicle regression: Catagen retardation in p75NTR knockout mice and after p75NTR blockade by cyclic peptides", <i>Journal of Investigative Dermatology</i> 112(4):553, 1999.	
		SCHWARZE, S. R. <i>et al.</i> , "Protein Transduction: Unrestricted Delivery Into All Cells?", <i>Trends in Cell Biology</i> , 10(7):290-295, 2000.	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).	